Human PlGF-4 Alexa Fluor™ Plus 594-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB2644AFP594
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunocytochemistry
Label
Alexa Fluor Plus 594 (Excitation = 590 nm, Emission = 618 nm)
Antibody Source
Monoclonal Mouse IgG2B Clone # 1039228
Product Specifications
Immunogen
Human embryonic kidney cell HEK293-derived human PlGF-4
Specificity
Detects human PIGF-4 in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Applications for Human PlGF-4 Alexa Fluor™ Plus 594-conjugated Antibody
Application
Recommended Usage
Immunocytochemistry
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Formulation
Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
Background: PlGF-4
(3-6). Circulating PlGF increases during pregnancy, reaching a peak in mid‑gestation; this increase is attenuated in preeclampsia (7). Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia (8). PlGF binds and signals through VEGF R1/Flt‑1 and Neuropilins (some isoforms), but not VEGF R2/Flk‑1/KDR (8-10). In contrast, VEGF binds both VEGF R1 and R2, but signals mainly through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, resulting in a PlGF inhibition of VEGF/VEGF R1 binding coupled to a subsequent promotion of VEGF/VEGF R2‑mediated angiogenesis (8, 9). However, PlGF (especially PlGF‑1) and some forms of VEGF can form heterodimers that alter the angiogenic effect of VEGF on VEGF R2 (4, 9). PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF (1). These activities facilitate wound and bone fracture healing and also contribute to inflammation in active sickle cell disease and atherosclerosis (1, 5, 6, 8, 11-13).
References
- Dewerchin, M. and P. Carmeliet (2012) Cold Spring Harb. Perspect. Med. 2:a011056.
- Cao, Y. et al. (1997) Biochem. Biophys. Res. Commun. 253:493.
- Yang, W. et al. (2003) J. Reprod. Immunol. 60:53.
- Eriksson, A. et al. (2002) Cancer Cell 1:99.
- Oura, H. et al. (2003) Blood 101:560.
- Roncal, C. et al. (2010) Cardiovasc. Res. 86:29.
- Levine, R.J. et al. (2004) N. Engl. J. Med. 350:672.
- Carmeliet, P. et al. (2001) Nat. Med. 7:575.
- Autiero, M. et al. (2003) Nat. Med. 9:936.
- Migdal, M. et al. (1998) J. Biol. Chem. 273:22272.
- Perelman, N. et al. (2003) Blood 102:1506.
- Cianfarani, F. et al. (2006) Am. J. Pathol. 169:1167.
- Maes, C. et al. (2006) J. Clin. Invest. 116:1230.
Long Name
Placenta Growth Factor 4
Alternate Names
PlGF4
Entrez Gene IDs
5228 (Human)
Gene Symbol
PGF
UniProt
Additional PlGF-4 Products
Product Specific Notices for Human PlGF-4 Alexa Fluor™ Plus 594-conjugated Antibody
This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.
For research use only
Loading...
Loading...
Loading...
Loading...